Sanofi (NASDAQ:SNY) Stake Raised by Capital Investment Counsel LLC

Capital Investment Counsel LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 5.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 66,487 shares of the company’s stock after acquiring an additional 3,468 shares during the period. Capital Investment Counsel LLC’s holdings in Sanofi were worth $3,832,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in SNY. Northwest Investment Counselors LLC acquired a new position in Sanofi during the 3rd quarter worth $29,000. POM Investment Strategies LLC bought a new stake in shares of Sanofi during the second quarter valued at about $25,000. Concord Wealth Partners lifted its holdings in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares during the period. Arrow Financial Corp bought a new position in Sanofi in the 2nd quarter valued at about $35,000. Finally, Fortitude Family Office LLC increased its stake in Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after buying an additional 659 shares during the period. 10.04% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on SNY. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $48.28 on Friday. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a 50-day moving average of $53.70 and a two-hundred day moving average of $52.17. The company has a market capitalization of $122.53 billion, a price-to-earnings ratio of 24.63, a PEG ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.55 earnings per share. As a group, analysts expect that Sanofi will post 4.29 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.